Interpreting lung function data using 80% predicted and fixed thresholds identifies patients at increased risk of mortality

Chest

Volumn 141, Issue 1, 2012, Pages 73-80

  Mannino, David M ^a,b   Diaz Guzman, Enrique ^b  

^a UNIVERSITY OF KENTUCKY COLLEGE OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE; HIGH RISK PATIENT; HUMAN; LOWER LIMIT OF NORMAL; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

EID: 80052769723     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-0797     Document Type: Article

References (36)

1. Mannino DM, Buist AS. Global burden of COPD:risk factors, prevalence, and future trends. Lancet. 2007;370(9589): 765-773. (Pubitemid 47321908)
2. Minino AM, Xu J, Kochanek KD. Death:preliminary data for 2008. Natl Vital Stat Rep. 2010;59(2):1-72.
3. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS; GOLD Scientifi c Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163(5):1256-1276. (Pubitemid 32378468)
4. Snider GL. Nosology for our day:its application to chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;167(5):678-683. (Pubitemid 36801741)
5. Rodriguez-Roisin R, Rabe KF, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2008 Update). GOLD Web site. http://www.goldcopd.org. Published 2009. Accessed April 26, 2011.
6. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995;152(5 pt 2):S77-S121.
7. Celli BR, MacNee W;ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD:a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932-946. (Pubitemid 38807371)
8. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005; 26 (5):948-968. (Pubitemid 41632054)
9. O'Reilly J, Jones MM, Parnham J, Lovibond K, Rudolf M; Guideline Development Group. Management of stable chronic obstructive pulmonary disease in primary and secondary care:summary of updated NICE guidance. BMJ. 2010;340:c3134.
10. Miller MR, Quanjer PH, Swanney MP, Ruppel G, Enright PL. Interpreting lung function data using 80% predicted and fi xed thresholds misclassifi es more than 20% of patients. Chest. 2011;139(1):52-59.
11. Enright P, Brusasco V. Counterpoint:should we abandon FEV/FVC, 0.70 to detect airway obstruction? Yes. Chest. 2010;138(5):1040-1042.
12. Quanjer PH, Enright PL, Miller MR, et alPulmonaria Group. Open letter:the need to change the method for defi ning mild airway obstruction. Prim Care Respir J. 2010;19(3):288-291.
13. Vaz Fragoso CA, Concato J, McAvay G, et al. Chronic obstructive pulmonary disease in older persons:a comparison of two spirometric defi nitions. Respir Med. 2010;104(8):1189-1196.
14. Mannino DM, Sonia Buist A, Vollmer WM. Chronic obstructive pulmonary disease in the older adult:what defi nes abnormal lung function? Thorax. 2007;62(3):237-241. (Pubitemid 46579804)
15. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999;159(1):179-187. (Pubitemid 29036522)
16. Rabe KF, Hurd S, Anzueto A, et alGlobal Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease:GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6):532-555. (Pubitemid 47403272)
17. 1. The Lung Health Study. JAMA. 1994;272(19):1497-1505.
18. Mannino DM, Watt G, Hole D, et al. The natural history of chronic obstructive pulmonary disease. Eur Respir J. 2006;27(3):627-643. (Pubitemid 43372539)
19. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance-United States, 1971-2000. MMWR Surveill Summ. 2002;51(6):1-16.
20. Celli BR, Halbert RJ. Point:should we abandon FEV/ FVC, 0.70 to detect airway obstruction? No. Chest. 2010 : 138(5):1037-1040.
21. Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA. 2005;294(10):1255-1259. (Pubitemid 41352114)
22. Lee TA, Pickard AS, Bartle B, Weiss KB. Osteoarthritis:a comorbid marker for longer life? Ann Epidemiol. 2007;17(5): 380-384. (Pubitemid 46629035)
23. Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States:prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord. 1998;22(1):39-47. (Pubitemid 28036587)
24. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med. 1998;158(17):1855-1867.
25. Decramer M, Cooper CB. Treatment of COPD:the sooner the better? Thorax. 2010;65(9):837-841.
26. Johannessen A, Omenaas ER, Bakke PS, Gulsvik A. Implications of reversibility testing on prevalence and risk factors for chronic obstructive pulmonary disease:a community study. Thorax. 2005;60(10):842-847. (Pubitemid 41475212)
27. Prentice HA, Mannino DM, Caldwell GG, Bush HM. Significant bronchodilator responsiveness and "reversibility" in a population sample. COPD. 2010;7(5):323-330.
28. Mannino DM, Doherty DE, Sonia Buist A. Global Initiative on Obstructive Lung Disease (GOLD) classifi cation of lung disease and mortality:fi ndings from the Atherosclerosis Risk in Communities (ARIC) study. Respir Med. 2006;100(1):115-122. (Pubitemid 43039873)
29. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005-1012. (Pubitemid 38269277)
30. Stavem K, Aaser E, Sandvik L, et al. Lung function, smoking and mortality in a 26-year follow-up of healthy middle-aged males. Eur Respir J. 2005;25(4):618-625. (Pubitemid 40528753)
31. Wenzel SE. Asthma:defi ning of the persistent adult phenotypes . Lancet. 2006;368(9537):804-813. (Pubitemid 44279058)
32. Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes:the future of COPD. Am J Respir Crit Care Med. 2010;182(5):598-604.
33. Decramer M, Rennard S, Troosters T, et al. COPD as a lung disease with systemic consequences-clinical impact, mechanisms, and potential for early intervention. COPD. 2008;5(4):235-256.
34. Mannino DM. Preventing COPD:evidence of progress. COPD. 2010;7(1):3-4.
35. Brown DW, Croft JB, Greenlund KJ, Giles WH. Trends in hospitalization with chronic obstructive pulmonary disease- United States, 1990-2005. COPD. 2010;7(1):59-62.
36. Polednak AP. Trends in mortality from COPD in selected U.S. States differing in tobacco control efforts. COPD. 2010;7(1):63-69.